Jazz Pharmaceuticals Plunges 3.84% Amid Patent Lawsuits

Jazz Pharmaceuticals (JAZZ) shares plummeted 3.84% today, marking the fourth consecutive day of decline, with a total drop of 18.68% over the past four days. The stock price hit its lowest level since July 2024, experiencing an intraday decline of 5.19%.

The primary factor influencing Jazz Pharmaceuticals' stock price in 2025 is the initiation of four patent infringement lawsuits by Avadel Pharmaceuticals. These legal actions, which began at the start of the year, target specific uses of Jazz's Xywav product. The potential impact on Jazz Pharmaceuticals' market position and investor sentiment could contribute to the volatility in its stock price.